Pre-existing subclinical hypothyroidism and low free thyroxine in patients undergoing immune checkpoint inhibitor therapies is a risk factor for overt hypothyroidism.

Front Endocrinol (Lausanne) · 2025 · PMC12640802 · PMID 41293744

Europe PMC DOI

hedged sentences

0.0660

closest p · 1.3× alpha

0.0680

boldest claim

The sentences

did not reach statistical significancep = 0.066so close (0.05 < p ≤ 0.1)

BMI was also higher in the overt dysfunction group, although this difference did not reach statistical significance (25.22 [IQR, 21.33–26.94] vs. 22.41 [IQR, 21.19–24.69] kg/m2; p = 0.066).

also in 111,027 other papers

showed a trendp = 0.068so close (0.05 < p ≤ 0.1)

Although the difference was not statistically significant, patients in the sABTF group showed a trend toward lower rates of smoking history (37.25% vs. 52.21%; p = 0.068) and were more likely to have received targeted therapy in combination with ICIs (35.29% vs. 19.12%; p = 0.059) ( Table 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.